| VRSK |
Report |
Revenue |
IN-LINE |
pred ~$806M vs. cons $804M |
MEDIUM |
| VRSK |
Report |
Adjusted EPS |
BEAT |
pred ~$1.97 vs. cons $1.94 |
MEDIUM |
| VRSK |
Report |
Organic constant-currency revenue growth |
BEAT |
pred ~5.3% vs. cons 5.0% |
MEDIUM |
| VRSK |
Guide |
FY2026 revenue guidance midpoint |
LOWER |
guide ~$3.215B vs. cons $3.230B (FY2026; prior range reaffirmed) |
HIGH |
| VRSK |
Guide |
FY2026 adjusted EBITDA guidance midpoint |
LOWER |
guide ~$1.810B vs. cons $1.820B (FY2026; prior range reaffirmed) |
MEDIUM |
| VRSK |
Guide |
FY2026 adjusted EPS guidance midpoint |
LOWER |
guide ~$7.60 vs. cons $7.65 (FY2026; prior range reaffirmed) |
HIGH |
| VRSK |
Guide |
Second-half organic constant-currency revenue growth commentary |
LOWER |
guide ~6.8% vs. cons 7.1% (2H2026) |
LOW |
| VRSK |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| VRSK |
Return |
5-day cumulative residual |
+0.6% (FADE) |
An adjusted EPS beat of ~$1.97 vs. $1.94 and OCC growth of ~5.3% vs. 5.0% support the initial move, but an unchanged FY2026 EPS midpoint of ~$7.60 vs. consensus $7.65 implies limited out-period upside and modest estimate cuts after the print. |
MEDIUM |